IP Library Granted Patent US 10,519,189
Granted Patent B2
US 10,519,189 · App. 16/232,435 · Granted Dec 31, 2019

Compositions and methods for synthesizing 5′-Capped RNAs

Inventors: Richard I. Hogrefe (San Diego, CA); Alexandre Lebedev (San Diego, CA); Anton P. McCaffrey (San Diego, CA); Dongwon Shin (San Diego, CA)
Assignee: TRILINK BIOTECHNOLOGIES, INC.
C07H21/02A23L33/13A61K31/711A61K31/712A61K31/7115C12N15/11C12P19/34C12Y207/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,519,189
App. No.
16/232,435
Granted
Dec 31, 2019
Kind
B2
Abstract

Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N 2′Ome ] n [N] m wherein m7 G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.

Claims (37)

1. A complex comprising an initiating capped oligonucleotide primer and a DNA template,

wherein the initiating capped oligonucleotide primer comprises a structure:

wherein

B 1 and B 2 are independently a natural, a modified, or an unnatural nucleoside base; and

R 1 , R 2 , and R 3 are independently OH or O-methyl;

wherein the DNA template comprises a promoter region comprising a transcriptional start site having a first nucleotide at nucleotide position +1 and a second nucleotide at nucleotide position +2; and

wherein the initiating capped oligonucleotide primer is hybridized to the DNA template at least at nucleotide positions +1 and +2.

2. The complex of claim 1 , wherein B 1 is at nucleotide position +1 and B 2 is at nucleotide position +2.

3. The complex of claim 1 , wherein B 1 and B 2 are natural nucleoside bases.

4. The complex of claim 1 , wherein at least one of B 1 and B 2 is a modified or an unnatural base.

5. The complex of claim 1 , wherein at least one of B 1 and B 2 is N6-methyladenine.

6. The complex of claim 1 , wherein B 1 is adenine and B 2 is guanine.

7. The complex of claim 1 , wherein B 1 is guanine and B 2 is guanine.

8. The complex of claim 1 , wherein B 1 is adenine and B 2 is uracil.

9. The complex of claim 1 , wherein R 3 is OH.

10. The complex of claim 1 , wherein R 3 is O-methyl.

11. The complex of claim 1 , wherein at least one of R 1 and R 2 is O-methyl, B 1 is adenine, and B 2 is guanine.

12. The complex of claim 1 , wherein at least one of R 1 and R 2 is O-methyl, and B 1 and B 2 are guanine.

13. The complex of claim 1 , wherein at least one of R 1 and R 2 is O-methyl, B 1 is adenine, and B 2 is uracil.

14. The complex of claim 1 , wherein B 1 is N6-methyladenine and B 2 is a natural, a modified, or an unnatural base.

15. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

16. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

17. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

18. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

19. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

20. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

21. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

22. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

23. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

24. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

25. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

26. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

27. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

28. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

29. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

30. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

31. The complex of claim 1 , wherein the initiating capped oligonucleotide primer comprises the structure:

Assignments (3)
CHANGE OF NAME Recorded Jul 29, 2022
From: TRILINK BIOTECHNOLOGIES, INCORPORATED
To: TRILINK BIOTECHNOLOGIES, LLC
Reel/Frame 061033/0215 →
SECURITY AGREEMENT Recorded Oct 19, 2020
From: MARAVAI LIFE SCIENCES, INC.; TRILINK BIOTECHNOLOGIES, LLC; VECTOR LABORATORIES, INC.; GLEN RESEARCH, LLC; CYGNUS TECHNOLOGIES, LLC; MOCKV SOLUTIONS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 054118/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2018
From: HOGREFE, RICHARD I.; MCCAFFREY, ANTON P.; SHIN, DONGWON; LEBEDEV, ALEXANDRE
To: TRILINK BIOTECHNOLOGIES, INC.
Reel/Frame 047853/0042 →
Cited By (5)
US 12,186,387 US 12,208,136 US 12,258,369 US 12,264,175 US 12,448,622